Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

New Prognostic Tool for Critically Ill Allo-SCT Patients

Biol Blood Marrow Transplant; ePub 2017 Mar 4; Bayraktar, et al

Publish date:: March 15, 2017

A new prognostic index for intensive care after allogeneic hematopoietic stem cell transplantation (allo-SCT) accurately predicted mortality in a study involving 656 individuals.

Investigators developed a prognostic index for critically ill allo-SCT patients. They used the tool in patients admitted to the MD Anderson Cancer Center ICU between 2001 and 2010. Among the results:

The new index outperformed both the APACHE II and SOFA scoring systems.
Hospital mortality using the new tool was 31% in patients with a 0-2 score; in those with scores >2-4 and >4 it was 69% and 91%, respectively.
Median overall survival in these groups were 7.59, 0.67, and 0.30 months, respectively.

Citation:

Bayraktar U, Milton D, Shpall E, et al. Prognostic index for critically ill allogeneic transplant patients. [Published online ahead of print March 4, 2017]. Biol Blood Marrow Transplant. doi:10.1016/j.bbmt.2017.03.003.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Myelodysplastic Syndrome

Second transplant a good salvage option for children with ALL, AML, or MDS,

Genetic analysis highlights value of germline variants in MDS, AML,

Antibody targeting ‘do not eat me’ signals is active in AML, MDS,

Combo proves most effective in HMA-naive, higher-risk MDS,

More abnormal cells linked to poorer ASCT outcomes in MDS,